Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma

Journal of Hematotherapy and Stem Cell Research

Volumn 12, Issue 4, 2003, Pages 435-442

  Tchirkov, Andrei ^a,b,c,f   Paillard, Catherine ^c   Halle, Pascale ^c   Bernard, Frédéric ^d   Bordigoni, Pierre ^e   Vago, Philippe ^b   Deméocq, François ^c   Kanold, Justyna ^c  

^a Centre de Lutte Contre le Cancer Jean Perrin   (France)

^b ONERA   (France)

^c HÔTEL DIEU   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

^e HÔPITAL D ENFANTS   (France)

^f CENTRE JEAN PERRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; TYROSINE 3 MONOOXYGENASE;

ARTICLE; AUTOGRAFT; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; MOLECULAR PROBE; NEUROBLAST; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR REGRESSION;

ANTIGENS, CD34; BONE MARROW CELLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM METASTASIS; NEUROBLASTOMA; NEURONS; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELLS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TYROSINE 3-MONOOXYGENASE;

EID: 0043025051     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581603322286060     Document Type: Article

References (22)

1. Haase GM, C Perez and JB Atkinson. (1999). Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin Surg Oncol 16:91-104.
2. Matthay KK, JB Atkinson, DO Stram, M Selch, CP Reynolds and RC Seeger. (1993). Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a children cancer group pilot study. J Clin Oncol 11:2226-2233.
3. Matthay KK, JG Villablanca, RC Seeger, DO Stram, RE Harris, NK Ramsay, P Swift, H Shimada, CT Black, GM Brodeur, RB Gerbing and CP Reynolds. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173.
4. Seeger RC, CP Reynolds, R Gallego, DO Stram, RB Gerbing and KK Matthay. (2000). Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a children's cancer group study. J Clin Oncol 18:4067-4076.
5. Tchirkov A, J Kanold, M Giollant, P Halle-Haus, M Berger, C Rapatel, P Lutz, C Bergeron, D Plantaz, JP Vannier, JL Stephan, M Favrot, P Bordigoni, P Malet, G Briançon and F Deméocq. (1998). Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 30:228-232.
6. Burchill SA, SE Kinsey, S Picton, P Roberts, CR Pinkerton, P Selby and IJ Lewis. (2001). Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 36:213-219.
7. Faulkner LB, A Garaventa, A Paoli, V Tintori, A Tamburini, L Lacitignola, M Veltroni, MS Lo Piccolo, E Viscardi, C Milanaccio, A Tondo, S Spinelli, G Bemini and B De Bernardi. (2000). In vivo cytoreduction studies and cell-sorting-enhanced tumor-cell detection in high-risk neuroblastoma patients: Implications for leukapheresis strategies. J Clin Oncol 18:3829-3836.
8. Burchill SA, FM Bradbury, B Smith, IJ Lewis and P Selby. (1994). Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer 57:671-675.
9. Brodeur GM, J Pritchard, F Berthold, NL Carlsen, V Castel, RP Castelberry, B De Bernardi, AE Evans, M Favrot, F Hedborg, M Kaneko, J Kemshead, F Lampert, REJ Lee, AT Look, ADJ Pearson, T Philip, B Roald, T Sawada, RC Seeger, Y Tsuchida and PA Voute. (1993). Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477.
10. + cell transplantation procedure using standard leukapheresis products in very small children. Bone Marrow Transplant 20:191-198.
11. Kanold J, K Yakouben, A Tchirkov, AS Carret, JP Vannier, E LeGall, P Bordigoni and F Demeocq. (2000). Long-term results of CD34(+) cell transplantation in children with neuroblastoma. Med Pediatr Oncol 35:1-7.
12. Max N, Wolf K, Thiel E, Keilholz U. (2002). Quantitative nested real-time RT-PCR specific for tyrosinase transcripts to quantitate minimal residual disease. Clin Chim Acta 317:39-46.
13. Ishida Y and Murai K. (2001). Development of quantitative RT-PCR for the expression of Wilms' tumor WT1 supressor gene in leukemia in the Lightcycler. In: Rapid Cycle Real-Time PCR. S Meuer, C Wittner and K Nakagawara, eds. Springer-Verlag, Heidelberg, pp 187-195.
14. Ratge D, B Scheiblhuber, O Landt, J Berg and C Knabbe. (2002). Two-round rapid-cycle RT-PCR in single closed capillaries increases the sensitivity of HCV RNA detection and avoids amplicon carry-over. J Clin Virol 24:161-172.
15. Fukuda M, Y Miyajima, Y Miyashita and K Horibe. (2001). Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol 23:10-13.
16. Burchill SA, IJ Lewis, KR Abrams, R Riley, J Imeson, AD Pearson, R Pinkerton and P Selby. (2001). Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 19:1795-1801.
17. + selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD immunocytochemistry. Eur J Cancer 33:2024-2030.
18. Leung W, AR Chen, RC Klann, TJ Moss, JM Davis, SJ Noga, KJ Cohen, AD Friedman, D Small, CL Schwartz, MJ Borowitz, MD Wharam, CN Paidas, CA Long, S Karandish, JD McMannis, MB Kastan and CI Civin. (1998). Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 22:971-979.
19. Brugger W, KJ Bross, M Glatt, F Weber, R Mertelsmann and L Kanz. (1994). Mobilization of tumor cells and transplantation progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636-640.
20. Moss TJ, M Cairo, VM Santana, J Weinthal, C Hurvitz and B Bostrom. (1994). Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood 83:3085-3089.
21. Rill DR, VM Santana, WM Roberts, T Nilson, LC Bowman, RA Krance, HE Helsop, RC Moen, JN Ihle and MK Brenner. (1994). Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383.
22. Handgretinger R, P Lang, K Ihm, M Schumm, A Geiselhart, E Koscielniak, B Hero, T Klingebiel and D Niethammer. (2002). Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant 29:731-736.